Supplemental Prospectus (SEC Filing - 424B4)

PROSPECTUS SUMMARY

The following summary highlights selected information contained elsewhere in this prospectus and in the documents incorporated by reference in this prospectus and does not contain all the information you will need in making your investment decision. You should read carefully this entire prospectus and the documents incorporated by reference in this prospectus before making your investment decision.

The Company

We are an externally managed REIT that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate focused on medical office buildings ("MOBs"), healthcare properties leased on a triple net basis ("NNN properties") and senior housing operating properties ("SHOPs"). As of June 30, 2021, we owned 195 properties located in 33 states and comprised of 9.1 million rentable square feet.

Substantially all of our business is conducted through the OP, a Delaware limited partnership, and its wholly owned subsidiaries. Our advisor, Healthcare Trust Advisors, LLC (the "Advisor") manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the "Property Manager"). Our Advisor and Property Manager are under common control with AR Global and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. Healthcare Trust Special Limited Partnership, LLC, which is also under common control with AR Global, also has an interest in us through ownership of interests in our OP.

Our principal executive offices are located at 650 Fifth Avenue, 30th Floor, New York, New York 10019. Our Investor Relations telephone number is (866) 902-0063. We maintain a website at www.healthcaretrustinc.com; however, the information on, or accessible through, our website is not incorporated into and does not constitute a part of this prospectus or any other report or document we file with or furnish to the SEC.

Recent Developments

Common Stock Dividend

On July 1, 2021, we declared a quarterly dividend payable in 0.014655 shares of common stock on each share of our common stock outstanding on July 1, 2021. The dividend was paid on July 15, 2021 to holders of record of common stock at the close of business on July 12, 2021.

Our estimated per share net asset value of our common stock (the "Estimated Per-Share NAV") was not adjusted to reflect the payment of these dividends and will not be adjusted for any future dividends in shares of common stock that we may pay in the future until we publish a new Estimated Per-Share NAV. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, each stockholder will receive the same number of new shares, the total value (using our Estimated Per-Share NAV) of our common stockholder's investment, all things equal, will not change assuming no sales or other transfers.

Acquisitions and Dispositions - Subsequent to June 30, 2021

Subsequent to June 30, 2021, we acquired six MOBs for an aggregate contract purchase price of approximately $123.9 million, which was funded primarily with cash on hand and borrowings from the revolving credit facility component (the "Revolving Credit Facility") of our senior secured credit facility (the "Credit Facility"), which consists of two components, the Revolving Credit Facility and a term loan (the "Term Loan"). The borrowings used to fund these acquisitions include $10 million borrowed under the Revolving Credit Facility in late August 2021 and an additional $74.6 million borrowed under our Revolving Credit Facility during September 2021. With respect to the acquisition of one MOB for a contract purchase price of $79.9 million completed on September 30, 2021, we satisfied our obligation to fund $2.5 million of the consideration by issuing to the seller 100,000 preferred units of our operating partnership which have economic interests that are substantially similar to the designations, preferences and other rights of the

Risk Factors Summary

An investment in the Series B Preferred Stock involves various risks. See "Risk Factors" beginning on page 11 of this prospectus and the documents incorporated by reference herein, before making a decision to invest in the Series B Preferred Stock. A summary of those risks is set forth below:

•

Our operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market in general.

​

•

Our property portfolio has a high concentration of properties located in Iowa, Pennsylvania and Florida. Our properties may be adversely affected by economic cycles and risks inherent to those states.

​

•

Our Credit Facility restricts us from paying cash distributions on or repurchasing our common stock until we make an election to do so and are able to meet certain leverage and liquidity conditions, which is not assured, and there can be no assurance we will be able to resume paying distributions on our common stock, and at what rate, or continue paying dividends on our Series B Preferred Stock at the current rate.

​

•

Our Credit Facility restricts our ability to use cash that would otherwise be available to us, and there can be no assurance our available liquidity will be sufficient to meet our capital needs.

​

•

We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic, including negative impacts on our tenants and operators and their respective businesses.

​

•

Listing on Nasdaq does not guarantee an active and liquid market for the Series B Preferred Stock, and the market price and trading volume of the Series B Preferred Stock may fluctuate significantly.

​

•

In owning properties we may experience, among other things, unforeseen costs associated with complying with laws and regulations and other costs, potential difficulties selling properties and potential damages or losses resulting from climate change.

​

•

We focus on acquiring and owning a diversified portfolio of healthcare-related assets located in the United States and are subject to risks inherent in concentrating investments in the healthcare industry.

​

•

The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of tenants to make lease payments to us.

​

•

We depend on tenants for our rental revenue and, accordingly, our rental revenue is dependent upon the success and economic viability of our tenants. If a tenant or lease guarantor declares bankruptcy or becomes insolvent, we may be unable to collect balances due under relevant leases.

​

•

We assume additional operational risks and are subject to additional regulation and liability because we depend on eligible independent contractors to manage some of our facilities.

​

•

We have substantial indebtedness and may be unable to repay, refinance, restructure or extend our indebtedness as it becomes due. Increases in interest rates could increase the amount of our debt payments. We may incur additional indebtedness in the future.

​

•

We depend on the Advisor and Property Manager to provide us with executive officers, key personnel and all services required for us to conduct our operations.

​

•

All of our executive officers face conflicts of interest, such as conflicts created by the terms of our agreements with the Advisor and compensation payable thereunder, conflicts allocating investment opportunities to us, and conflicts in allocating their time and attention to our matters. Conflicts that arise may not be resolved in our favor and could result in actions that are adverse to us.

​

•

We have long-term agreements with our Advisor and its affiliates that may be terminated only in limited circumstances and may require us to pay a termination fee in some cases.

​

•

Estimated Per-Share NAV may not accurately reflect the value of our assets and may not represent what a stockholder may receive on a sale of the shares, what they may receive upon a liquidation of our assets and distribution of the net proceeds or what a third party may pay to acquire us.

​

•

The stockholder rights plan adopted by our board, our classified board and other aspects of our corporate structure and Maryland law may discourage a third party from acquiring us in a manner that might result in a premium price to our stockholders.

​

•

Restrictions on share ownership contained in our charter may inhibit market activity in shares of our stock and restrict our business combination opportunities.

​

•

We may fail to continue to qualify as a REIT.

​

The Offering

The following summarizes the material terms of this offering. For a more complete description of the terms of the Series B Preferred Stock, see "Description of Capital Stock and Securities Offered" in this prospectus.

Issuer

Healthcare Trust, Inc., a Maryland corporation.

Securities Offered

3,200,000 shares of Series B Preferred Stock (plus up to an additional 480,000 shares if the underwriters exercise their option to purchase additional shares of Series B Preferred Stock in full). We reserve the right to reopen this series and issue additional shares of Series B Preferred Stock either through public or private offerings and sales at any time.

Ranking

The Series B Preferred Stock will rank, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up:

•

senior to our common stock and to all other equity securities ranking junior to the Series B Preferred Stock;

​

•

on parity with the Series A Preferred Stock and all other equity securities ranking on parity with the Series B Preferred Stock; and

​

•

junior to any class or series of equity securities ranking senior to the Series B Preferred Stock.

​

The authorization or issuance of equity securities ranking senior to the Series B Preferred Stock will require the affirmative vote of the holders of at least two-thirds of the outstanding shares of Series B Preferred Stock. Any convertible debt securities that we may issue will not be considered to be "equity securities" for these purposes prior to the time of conversion. The Series B Preferred Stock ranks junior to all our existing and future indebtedness. The terms of the Series B Preferred Stock will not limit our ability to: (1) incur indebtedness; or (2) issue additional equity securities that rank junior to, or on parity with, the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up.

Dividend Rate and Payment Dates

Holders of Series B Preferred Stock are entitled to receive cumulative dividends in the amount of $1.78125 per share each year, which is equivalent to the rate of 7.125% of the $25.00 liquidation preference per share per annum. Dividends are cumulative and payable quarterly in arrears on the 15th day of each of January, April, July and October of each year, or, if not a business day, the next succeeding business day, to all holders of record on the applicable record date, when and as authorized by our board and declared by us. The first quarterly dividend for the Series B Preferred Stock sold in this offering will be paid on January 18, 2022 in an amount equal to $0.42057 per share, covering the period from October 6, 2021 to December 31, 2021. Dividends on the Series B Preferred Stock will continue to accrue even if our board does not authorize or we do not declare the dividends. See "Description of Capital Stock and Securities Offered - Preferred Stock - Series B Preferred Stock -  Dividends."

Liquidation Preference

If we liquidate, dissolve or wind up, the holders of Series B Preferred Stock will have the right to receive $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the date of payment, before any payments are made to the holders of our common stock or any other shares of capital stock that rank junior to the Series B Preferred Stock with respect to liquidation rights.

Optional Redemption

The Series B Preferred Stock will not be redeemable prior to October 6, 2026, except pursuant to provisions relating to preserving our qualification as a REIT and as described under the caption "Special Optional Redemption" below.

On and after October 6, 2026, the Series B Preferred Stock will be redeemable at our option for cash, in whole or in part, at any time or from time to time, at a price per share equal to $25.00, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on this payment date will be included in the redemption price), on each share of Series B Preferred Stock to be redeemed.

Special Optional Redemption

During any period of time (whether before or after October 6, 2026), the Series B Preferred Stock ceases to be listed on the Nasdaq Stock Market, the New York Stock Exchange (the "NYSE") or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC (a "Delisting Event"), we will have the option, subject to certain conditions, to redeem the outstanding Series B Preferred Stock, in whole or in part, after the Delisting Event, for a redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in the redemption price), on each share of Series B Preferred Stock to be redeemed.

Upon the occurrence of a Change of Control, we may, at our option, redeem the shares of Series B Preferred Stock, in whole or in part and within 120 days after the first date on which the Change of Control occurred, by paying $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date for and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on such payment date will be included in the redemption price).

A "Change of Control" occurs when, after the original issuance of the Series B Preferred Stock, the following have occurred and are continuing:

•

the acquisition by any person, including any syndicate or group deemed to be a "person" under Section 13(d)(3) of

​

the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger, conversion or other acquisition transaction or series of purchases, mergers, conversions or other acquisition transactions, of shares of our stock entitling that person to exercise more than 50% of the total voting power of all outstanding shares of our stock entitled to vote generally in the election of directors (except that the person will be deemed to have beneficial ownership of all securities that the person has the right to acquire, whether the right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and

•

following the closing of any transaction referred to in the bullet point above, neither we nor the acquiring or surviving entity, or a parent of us or the acquiring or surviving entity, has a class of common equity securities listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE, or the NYSE American LLC.

​

Change of Control Conversion Right

Upon the occurrence of a Change of Control during a continuing Delisting Event (each as defined herein), unless we have elected to exercise our redemption right, holders of the Series B Preferred Stock will have the right to convert some or all of the Series B Preferred Stock held by such holder into a number of shares of our common stock, par value $0.01 per share, per share of Series B Preferred Stock, which is equal to the lesser of:

•

the quotient obtained by dividing (i) the sum of the $25.00 liquidation preference per share of Series B Preferred Stock to be converted plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared) on the Series B Preferred Stock to, but not including, the Conversion Date (unless the Conversion Date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in this sum), by (ii) the Common Stock Price; and

​

•

3.4483, the Share Cap, subject to certain adjustments;

​

•

subject, in each case, to provisions for the receipt of alternative consideration as described in this prospectus. See "Description of Capital Stock and Securities Offered - Preferred Stock - Series B Preferred Stock - Change of Control Conversion Right" in this prospectus.

​

If, prior to the Conversion Date, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series B Preferred Stock will not have any right to convert their shares of Series B Preferred Stock so called for redemption in connection with a Change of Control during a continuing Delisting Event and any shares of Series B Preferred Stock subsequently

selected for redemption that have been tendered for conversion will be redeemed on the related redemption date instead of converted on the Conversion Date.

For definitions of "CoC Conversion Right," "Conversion Date" and "Common Stock Price," and for a description of the adjustments and provisions for the receipt of alternative consideration that may be applicable to the CoC Conversion Right, see "Description of Capital Stock and Securities Offered - Preferred Stock - Series B Preferred Stock - Change of Control Conversion Right" in this prospectus.

Except as provided above in connection with the CoC Conversion Right, the shares of Series B Preferred Stock are not convertible into or exchangeable for any other securities or property.

Voting Rights

Holders of Series B Preferred Stock will have only the following limited voting rights. If dividends on any outstanding shares of Series B Preferred Stock have not been paid for six or more quarterly periods (whether or not authorized or declared or consecutive), holders of Series B Preferred Stock and holders of any other class or series of preferred stock ranking on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up and upon which like voting rights have been conferred and are exercisable, including the Series A Preferred Stock, and with which the holders of Series B Preferred Stock are entitled to vote together as a single class, will have the exclusive power, voting together as a single class, to elect two additional directors until all accrued and unpaid dividends on the Series B Preferred Stock have been fully paid. In addition, we may not authorize or issue any class or series of equity securities ranking senior to the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up (including securities convertible into or exchangeable for any senior securities) or amend our charter (whether by merger, consolidation or otherwise) to materially and adversely change the terms of the Series B Preferred Stock without the affirmative vote of at least two-thirds of the votes entitled to be cast collectively on the matter by holders of outstanding shares of Series B Preferred Stock and holders of any other similarly-affected classes and series of preferred stock ranking on parity with the Series B Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up and upon which like voting rights have been conferred and are exercisable, voting together as a single class. Holders of Series B Preferred Stock will not have any voting rights in connection with any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series B Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, whether or not we are the surviving entity, if the Series B Preferred Stock (or stock into which the Series B Preferred Stock has been converted in any successor person or entity to us) remains outstanding with the terms thereof unchanged in all material respects or is exchanged for stock of the successor person or entity with substantially identical

rights, taking into account that, upon the occurrence of an event described in this sentence, we may not be the surviving entity. See "Description of Capital Stock and Securities Offered - Preferred Stock - Series B Preferred Stock - Voting Rights."

No Maturity, Sinking Fund or Mandatory Redemption

The Series B Preferred Stock will have no stated maturity date and will not be subject to mandatory redemption or any sinking fund. We will be neither required to redeem the shares of Series B Preferred Stock nor set apart funds to redeem the shares of Series B Preferred Stock. Accordingly, the shares of Series B Preferred Stock will remain outstanding indefinitely unless we decide to redeem them for cash or, under the limited circumstances where the holders of Series B Preferred Stock have a conversion right and decide to convert the shares of Series B Preferred Stock.

Restrictions on Transfer and Ownership

Our charter contains restrictions on the ownership and transfer of shares of our common stock and other outstanding shares of stock, including the Series B Preferred Stock. The relevant sections of our charter provide that, subject to certain exceptions, no person or entity may own, or be deemed to own, by virtue of the applicable constructive ownership provisions of the Internal Revenue Code of 1986, as amended (the "Code"), more than 9.8% in value of the aggregate of our outstanding shares of stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of our shares of stock. See "Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws - Restrictions on Transfer and Ownership of Stock."

Information Rights

During any period in which we are not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and any shares of Series B Preferred Stock are outstanding, we will: (1) transmit by mail or other permissible means under the Exchange Act to all holders of Series B Preferred Stock as their names and addresses appear in our record books and without cost to the holders, copies of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we would have been required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act if we were subject thereto (other than any exhibits that would have been required) within 15 days after the respective dates by which we would have been required to file these reports with the SEC if we were subject to Section 13 or 15(d) of the Exchange Act; and (2) within 15 days following written request, supply copies of these reports to any prospective holder of Series B Preferred Stock.

Listing

We have applied to list the Series B Preferred Stock on Nasdaq under the symbol "HTIBP." If the listing is approved, we expect trading to commence within 30 days after initial delivery of the shares of Series B Preferred Stock.

Delisting Penalty

Upon the occurrence of a Delisting Event, the dividend rate specified will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.125% of the $25.00 per share stated liquidation preference per annum (equivalent to $2.28125 per annum per share) from and as of the date of the Delisting Event. Following the cure of a Delisting Event, the dividend

rate will revert to the rate of 7.125% of the $25.00 per share stated liquidation preference per annum.

Book-Entry Form

The Series B Preferred Stock is issued and maintained in book-entry form registered in the name of the nominee of DTC. Shares of Series B Preferred Stock are eligible for the Direct Registration System service offered by the DTC and may be represented in the form of uncertificated or certificated shares, provided, however, that any holder of certificated shares of Series B Preferred Stock and, upon request, every holder of uncertificated shares of Series B Preferred Stock is entitled to have a certificate for shares of Series B Preferred Stock signed by, or in the name of, the Company in accordance with the articles supplementary relating to the Series B Preferred Stock.

Use of Proceeds

We estimate that the net proceeds from this offering, after deducting the underwriting discount but not other estimated offering expenses payable by us, will be approximately $77.5 million (approximately $88.8 million if the underwriters exercise their option to purchase additional shares of Series B Preferred Stock in full). We will contribute these net proceeds to our operating partnership in exchange for preferred units of our operating partnership which have economic interests that are substantially similar to the designations, preferences and other rights of the Series B Preferred Stock. We, acting through our operating partnership, will use the net proceeds from this contribution to repay amounts outstanding under the Revolving Credit Facility as required by the Credit Facility. Subject to the terms and conditions set forth in the Revolving Credit Facility, we may then draw on the Revolving Credit Facility to borrow any amounts so repaid for general corporate purposes, including purchases of additional properties.

Material U.S. Federal Income Tax Considerations

See "Material U.S. Federal Income Tax Considerations" in this prospectus.